Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...

Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors For the past 25 years, TIME’s Best ...

Management stated, the raising guidance going forward, it is primarily being driven by what we're seeing in the Mechanical Thrombectomy and NanoKnife spaces. Stephen Trowbridge said, We expect both to ...

In this episode of Let's Talk Medtech, AngioDynamics CEO James Clemmer shared insights into what has been a transformative year for the medical device company across multiple therapeutic areas.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options ...

AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid fourth-quarter fiscal 2025 performance, ...